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July 3, 2012:80–42 ULN; 3) serum aminotransferase levels were elevated and
accompanied by possible signs or symptoms of hepatic injury; or
4) the event was assessed as medically serious by medical reviewers
for any other reason.
In the 3.5-year period from June 15, 2007, to December 14,
2010, 10,927 patients were exposed to marketed ambrisentan in
the United States with a total exposure representing 9,893 patient-
years (Fig. 1). The mean time on ambrisentan was 330.5 days, with
62% of patients on ambrisentan for longer than 3 months and 50%
longer than 6 months. The LEAP database included 314 (2.87%)
post-marketing spontaneous reports of possible hepatic injury, of
which 156 (1.43%) were medically confirmed. A total of 77
medically confirmed cases did not meet the criteria of clinically
significant hepatic events (all of these cases reported small or
unspecified elevations in liver function tests) with 79 (0.72%)
remaining as clinically significant hepatic events. Six of the 79
clinically significant hepatic events had both elevated aspartate and
alanine aminotransferase 3 ULN and serum total bilirubin
2 ULN and were considered as potential Hy’s Law cases (Hy’s
Law is defined as 3 ULN for serum alanine or aspartate
aminotransferase and serum total bilirubin 2 ULN), with no
other reason to explain the combined increase and is considered a
marker of possible drug-induced liver injury (3). In 5 of the 6
reports, probable alternative causes of the hepatic events were
reported, with the sixth case having intermittent enzyme elevations
for 2 years and a poorly documented medical history. Possible
alternative causes or contributory factors for the hepatic events
were also present in 55 of the 73 remaining medically confirmed
clinically significant cases, and in 38 of these, ambrisentan was
successfully restarted.
PAH is itself associated with congestive liver disease due to
transient or progressive right ventricular dysfunction. PAH pa-
tients may also have abnormal serum aminotransferases due to
concomitant medical conditions such as underlying diseases that
cause secondary PAH. In placebo-treated patients in published
clinical trials for ERA, background incidence of elevated amino-
transferase levels of up to 6% has been reported in patients with
PAH (4). In normal populations, 1% to 4% may also have an
isolated or transient elevation of liver transaminases (5).
Differences in the structure of different ERAs may underlie
differences in hepatic safety profiles. Bosentan and sitaxsentan are
both sulfonamide-based, whereas ambrisentan is propanoic acid–
based. As such, the compounds may have different effects on
hepatocytes. In vitro analysis using sandwich-cultured human
hepatocytes reveals that both bosentan and sitaxsentan reduced
hepatic transport pumps. Ambrisentan, in contrast, showed no
inhibition of influx or efflux pumps (6).
Based on the LEAP data, in March 2011, the FDA removed
the requirement for mandatory monthly monitoring of LFT with
ambrisentan therapy (the monitoring for pregnancy and the black
box warning against the use of ambrisentan in pregnancy was
maintained, in keeping with the known teratogenicity of ERA).
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Letters to the Editor
Human Papillomavirus
and Cardiovascular Disease
We read with great interest the report byHsu-Ko Kuo and Ken Fujise
(1) titled “Human Papillomavirus and Cardiovascular Disease Among
.S. Women in the National Health and Nutrition Examination
urvey, 2003 to 2006,” recently published in the Journal.
The investigators report an association between the presence of
uman papillomavirus (HPV) deoxyribonucleic acid in the vagina
nd the risk for cardiovascular disease (CVD) in a population of
omen who participated in a national health and nutritional
urvey. They made the assumption that after HPV infection, the 2
ajor viral oncoproteins, E7 and E6, through their pRB and p53
egradation properties, may favor the development of atheroscle-
osis. The investigators argued that knock out for either p53 or
RB atherosclerosis development was accelerated in mice models.
owever, we would like to make some points that should be
iscussed in greater depth.
First, the overall HPV prevalence was high in the cohort. Kuo
nd Fujise (1) reported HPV deoxyribonucleic acid in 48% of
omen, 25% being infected by high-risk HPV, with a mean age of
5 years. Large epidemiological studies have reported a high HPV
revalence (up to 30% to 40%) in young women (age 20 to 24
ears), while the prevalence decreases to 10% or less in women
lder than 35 years (2,3).
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reportedly different from women included in the analysis. The
investigators indicated that they were younger and thus more likely
to harbor HPV deoxyribonucleic acid but probably less likely to
present CVD than the “responders.”
Third, of the 44 women with cervical cancer listed in the their
Table 1 (1), 22 were HPV negative. This is not consistent with the
fact that HPV is the etiologic agent for cervical cancer.
Fourth, in their Table 3, Kuo and Fujise (1) presented the odds
ratios (ORs) for CVD comparing women with cancer-associated
HPV types or other HPV types with those who are negative for
HPV. In the first model, the OR was 2.87 for women with
cancer-associated HPV types. The OR was 2.13 for women with
other HPV types, namely, low-risk HPV types that are not able to
induce p53 and pRB degradation. If the physiopathology hypoth-
esis is correct, we would expect a nonsignificant OR. As for models
2, 3, and 4, we would also expect lower ORs for CVD in women
with other HPV types.
Finally, the overall physiopathology hypothesis is very unlikely.
Indeed, HPV fails to produce classic viremia. Rather the virus
replicates locally until it is cleared by an efficient immune response.
In case of viral persistence, the virus remains localized to the site of
infection, and associated lesions can occur after an increased
expression of E6 and E7. The virus does not disseminate through-
out the body. It is therefore very unlikely that E6 and E7 have a
systemic effect leading to atherosclerosis.
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Reply
We thank Dr. Prétet and colleagues for their insightful comments
on our report (1). Brief, point-by-point responses provided here
illuminate the need for further research on the link between human
papillomavirus (HPV) infection and atherosclerosis.
First, on the basis of recent survey from the National Health
and Nutrition Examination Survey 2003 to 2006, the weighted
prevalence of genital HPV infection among 2,787 women wasestimated to be 44.5% (2), which is close to the unweighted
prevalence we reported (46.6%) (1). Using the research use–only
Linear Array genotyping assay (Roche Diagnostics GmbH,
Mannheim, Germany) has resulted in a higher HPV prevalence
than previously reported (3).
Second, we do not know if the “nonresponders” (n  543) were
more likely to harbor HPV deoxyribonucleic acid, because they did
not submit swab specimens or submitted inadequate swab speci-
mens. The crude prevalence of cardiovascular disease (CVD)
among responders and nonresponders was 2.6% and 2.2%, respec-
tively (p  0.612).
Third, ascertainment of cervical cancer was by self-report and
may have suffered from recall bias and a certain degree of
disagreement as to “true measures” of cervical cancer compared to
“self-report.” We reanalyzed the data for the HPV-CVD associ-
ation without using self-reported cervical cancer as a covariate, and
the results were the same.
Fourth, the association between other HPV types and CVD was
significant in model 1 (odds ratio: 2.13; 95% confidence interval:
1.12 to 4.06) but not in models 2 to 5. Low socioeconomic status,
associated with both HPV infection and CVD, is an important
confounder for which we were not able to control (4).
Finally, although the mechanism by which HPV infection could
promote atherosclerosis remains unknown, several possibilities
exist. First, chronic local inflammation caused by HPV infection
and resultant circulatory inflammatory mediators can facilitate
atherosclerosis as seen in Porphyromonas gingivalis infection (5).
Second, macrophages and monocytes (M) recruited to HPV-
infected tissue (6,7) can take up the virus (8), leading to the
degradation of M-p53 by E6 and E7. HPV-infected M can
then enter atherosclerotic plaques and facilitate atherosclerosis.
The lack of functional p53 in M facilitates atherosclerosis in
mouse models of atherosclerosis (9,10). These hypotheses, al-
though plausible, need to be experimentally tested.
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